AnaptysBio’s etokimab fails in moderate-to-severe atopic dermatitis

pharmafile | November 11, 2019 | News story | Sales and Marketing AnaptysBio; atopic dermatitis, pharma 

AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis.

The company revealed that, in a study of 300 adult participants, the drug had failed to show superior benefit in the treatment of the condition according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment compared to placebo, falling short of the trial’s primary endpoint.

“We are surprised and very disappointed by the topline results of the ATLAS trial,” said Hamza Suria, President and Chief Executive Officer of AnaptysBio. “We would like to thank all involved in the participation and support of the ATLAS study, including the patients, the investigators, their staff and our employees.  We look forward to continuing our strategy of advancing our wholly-owned clinical and preclinical pipeline programmes.”

The news has led AnaptysBio to halt another Phase 2b trial investigating the drug in the treatment of eosinophilic asthma in around 400 patients. However, the company confirmed that another trial, investigating around the drug’s efficacy in approximately 100 participants with chronic rhinosinusitis with nasal polyps will continue, with interim analysis results expected in the first quarter of 2020.

Matt Fellows

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content